Here is a link and a few excerpts from a PRNewswire article yesterday: XTL Completes Acquisition of Bio-Gal:
XTL is engaged in the development of therapeutics to treat diseases for which no medical cure has yet been discovered. The Company is focused on developing a drug for the treatment of multiple myeloma and Hepatitis C.
– Research and Clinical Observations of MM Terminal Patients by Bio-Gal Suggests That Treatment with Erythropoietin Suppresses the Disease, Prolonging and Improving the Patients’ Lives.
– XTL is Commencing Preparations to Begin a Phase 2 Clinical Trial in Multiple Myeloma Patients.
I am not familiar with erythropoietin. Research is currently being conducted in Isreal. Prof. Moshe Mittelman, a hematologist of international repute and director of the Division of Internal Medicine at Ichilov Hospital in Tel Aviv, reports ” Erythropeietin is helpful in suppressing the disease by “strengthening” the immune-system function, prolonging survival and inducing improvement in the quality of life.”
Keep these new anti-myeloma therapies coming! The more the better.
Feel good and keep smiling! Pat